HCW Biologics Inc (nasdaq:HCWB) Share Price

Company Profile

Business description
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
Contact
2929 N. Commerce Parkway
MiramarFL33025
USA
T: +1 954 842-2024
https://www.hcwbiologics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
35

Recommended

SpaceX has risen 50% from its IPO price to become the second-most-expensive stock under Morningstar’s coverage.

Tom Lauricella | 19 June 2026

Even as competition looks likely to build, the company remains a leading wide-moat business securely at the center of the AI ecosystem.

Brian Colello, CPA | 19 June 2026

Most Australians will end up owning SpaceX — whether they like it or not.

Tyger Fitzpatrick | 19 June 2026

Index	Last price	Change	% Change
All Ordinaries	9,045.50	27.70	-0.31%
CAC 40	8,467.98	37.19	0.44%
DAX 40	25,026.80	92.13	0.37%
Dow JONES (US)	51,564.70	72.15	0.14%
FTSE 100	10,399.70	108.91	-1.04%
HKSE	23,924.81	387.35	-1.59%
NASDAQ	26,517.93	496.28	1.91%
Nikkei 225	71,608.72	555.23	0.78%
NZX 50 Index	13,416.34	53.03	0.40%
S&P 500	7,500.58	80.48	1.08%
S&P/ASX 200	8,827.00	29.60	-0.33%
SSE Composite Index	4,090.48	17.59	-0.43%